SCHEMBL5375744

SCHEMBL5375744

CCc1ccc(-c2nc(CCOCC#CCSCC(=O)OC)c(C)o2)cc1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 11/20 0.50
SMN1; SMN2 Q16637 7/20 0.50
POLB P06746 4/20 0.50
ALDH1A1 P00352 5/20 0.47
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
NCOA3 Q9Y6Q9 1/20 0.47
HSD17B10 Q99714 3/20 0.46
HTT P42858 2/20 0.45
HPGD P15428 2/20 0.45
LMNA P02545 1/20 0.45
MAPK1 P28482 1/20 0.45
RXFP1 Q9HBX9 1/20 0.45
KDM4E B2RXH2 6/20 0.44
RAB9A P51151 1/20 0.44
TSHR P16473 1/20 0.44
PPARG P37231 1/20 0.42
PPARA Q07869 1/20 0.42
TP53 P04637 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5365636 0.94 RXFP1 (0.46) MAPTSMN1; SMN2POLBALDH1A1MEN1
SCHEMBL5374028 0.92 RXFP1 (0.49) MAPTSMN1; SMN2POLBALDH1A1MEN1
SCHEMBL5367314 0.91 KDM4E (0.50) MAPTSMN1; SMN2POLBALDH1A1MEN1
SCHEMBL5377424 0.90 PPARG (0.48) MAPTSMN1; SMN2HSD17B10KDM4EPPARG
SCHEMBL5374332 0.84 RXFP1 (0.43) MAPTSMN1; SMN2ALDH1A1HSD17B10RXFP1
SCHEMBL5373806 0.84 HSD17B10 (0.39) MAPTSMN1; SMN2POLBALDH1A1MEN1
SCHEMBL5376066 0.83 MAPK1 (0.50) MAPTSMN1; SMN2ALDH1A1KMT2AHSD17B10
SCHEMBL5369422 0.82 HSD17B10 (0.53) MAPTSMN1; SMN2POLBALDH1A1MEN1
SCHEMBL5367857 0.82 PPARG (0.48) MAPTSMN1; SMN2POLBALDH1A1HSD17B10
SCHEMBL5377212 0.81 PPARG (0.53) HPGDKDM4EPPARGPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040087636-A1 Carboxylic acid derivative and a pharmaceutical composition containing the derivative as active ingredient ONO PHARMACEUTICAL CO., LTD. 2004-05-06 US claimed
US-6664281-B1 Oxazol-4-yl-alkoxy- or alkthioxy- functionality; peroxisome proliferator activated receptor regulators ONO PHARMACEUTICAL CO., LTD. (JP) 2003-12-16 US claimed
EP-1108713-A1 CARBOXYLIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2001-06-20 EP claimed
US-7241784-B2 Carboxylic acid derivative and a pharmaceutical composition containing the derivative as active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2007-07-10 US disclosed
US-7241784-B2 Carboxylic acid derivative and a pharmaceutical composition containing the derivative as active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2007-07-10 US disclosed
US-7241784-B2 Carboxylic acid derivative and a pharmaceutical composition containing the derivative as active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2007-07-10 US disclosed
US-20040087636-A1 Carboxylic acid derivative and a pharmaceutical composition containing the derivative as active ingredient ONO PHARMACEUTICAL CO., LTD. 2004-05-06 US disclosed
US-6664281-B1 Oxazol-4-yl-alkoxy- or alkthioxy- functionality; peroxisome proliferator activated receptor regulators ONO PHARMACEUTICAL CO., LTD. (JP) 2003-12-16 US disclosed
EP-1108713-A1 CARBOXYLIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2001-06-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040087636-A1 Carboxylic acid derivative and a pharmaceutical composition containing the derivative as active ingredient PPARA, PPARG, PPARD MAPT 3171/4885SMN1; SMN2 4797/4885POLB 2953/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.